Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis

Gastro Hep Advances

Aug 26

Written by Matthijs Versteegh

CrohnCost-utility

Matthijs Versteegh

Cost–Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn’s Disease

Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine